Henness Sheridan, Perry Caroline M
Adis International Limited, Mairangi Bay, Auckland, New Zealand.
Drugs. 2006;66(12):1625-56. doi: 10.2165/00003495-200666120-00012.
Orlistat (Xenical) is a reversible inhibitor of gastric and pancreatic lipases. In conjunction with a hypocaloric diet and moderate exercise, orlistat is an effective drug for use in the management of obesity in adults with or without comorbidities. Recent data have shown that orlistat is also effective as a component of weight management strategies in obese adolescents. In addition to its well established efficacy in achieving modest weight loss, orlistat has been shown to improve glycaemic parameters in obese adults with type 2 diabetes mellitus as well as some features of the metabolic syndrome. Orlistat is generally well tolerated. Thus, orlistat is an option for the treatment of obese patients with or without type 2 diabetes and also has a role in the management of obese patients with the metabolic syndrome, associated comorbidities or concomitant disorders.
奥利司他（赛尼可）是胃脂肪酶和胰脂肪酶的可逆性抑制剂。与低热量饮食及适度运动相结合，奥利司他是用于治疗有或无合并症的成年肥胖者的有效药物。近期数据表明，奥利司他作为肥胖青少年体重管理策略的一部分同样有效。除了在实现适度体重减轻方面已确立的疗效外，奥利司他还被证明可改善患有2型糖尿病的肥胖成年人的血糖参数以及代谢综合征的一些特征。奥利司他一般耐受性良好。因此，奥利司他是治疗有或无2型糖尿病的肥胖患者的一种选择，并且在管理患有代谢综合征、相关合并症或伴随疾病的肥胖患者中也发挥作用。
